Physician profile
Brian Maddox
NPI 1588002554
$5,529.08
in general payments reported to CMS, 2019-2025
35 companies · $971 in 2025
The $971 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $468 · 2020: $289 · 2021: $809 · 2022: $883 · 2023: $1,022 · 2024: $1,087 · 2025: $971.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,081.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,081.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,574.60 | 2021-2025 | |
| Lilly USA, LLC | $730.82 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $678.05 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $586.42 | 2021-2025 | Trintellix |
| Pfizer INC. | $332.27 | 2021-2025 | |
| Amgen INC. | $206.14 | 2021-2025 | Evenity, Repatha, Otezla |
| Astrazeneca Pharmaceuticals Lp | $165.95 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Allergan, INC. | $145.92 | 2019-2021 | |
| Exact Sciences Corporation | $129.71 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $110.13 | 2019-2024 | Arexvy, Boostrix, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.09 | 2019-2024 | Ofev |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $98.87 | 2024-2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $95.07 | 2022-2024 | Quviviq |
| Nevro Corp. | $81.74 | 2022-2023 | Senza |
| Sunovion Pharmaceuticals INC. | $47.72 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | $40.89 | 2022 | |
| Janssen Pharmaceuticals, INC | $40.23 | 2023 | Spravato |
| Ironshore Pharmaceuticals INC. | $38.17 | 2019 | |
| Antares Pharma, INC. | $34.38 | 2021-2025 | Xyosted |
| Shire North American Group INC | $31.57 | 2019 | |
| Astellas Pharma US INC | $28.61 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.72 | 2019-2020 | |
| Axsome Therapeutics, INC. | $25.19 | 2023 | Auvelity |
| Merck Sharp & Dohme LLC | $24.31 | 2019-2020 | |
| Corcept Therapeutics | $18.33 | 2023 | Korlym |
| Merz North America, INC. | $18.28 | 2019 | |
| Amarin Pharma, INC. | $16.92 | 2020 | |
| Lundbeck LLC | $16.45 | 2019 | |
| Abbott Laboratories | $14.38 | 2025 | Freestyle Libre 3 |
| Biohaven Pharmaceuticals, INC. | $14.36 | 2021 | |
| Medline Industries Lp | $12.82 | 2020 | |
| Daiichi Sankyo INC. | $12.68 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $11.58 | 2020 | |
| Sanofi-Aventis U.S. LLC | $10.91 | 2019 | |
| Grt US Holding, INC. | $9.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Maddox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.